Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Recent advances in acute myeloid leukemia (AML) biology and its genetic landscape
should ultimately lead to more subset-specific AML therapies, ideally tailored to each …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation
(HSCT) on adults with intermediate-or high-risk acute myeloid leukemia (AML) in the first …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid
leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …

Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …

Background Mutations occur in several genes in cytogenetically normal acute myeloid
leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 …